What is JAZZ's five-year median EV/EBITDA?

16.6x. Half of JAZZ's weekly readings over the last five years were higher and half were lower. This page has 765 weekly readings, from Feb 27, 2012 to Oct 19, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares JAZZ only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Jazz Pharmaceuticals PLC (JAZZ) valuation history

Health Care

$214.00

Latest weekly close · Market cap $14.9B

Below its usual range

As of Oct 24, 2026

JAZZ's EV/EBITDA of 10.9x is lower than 71% of its weekly readings over the last five years.

Weekly EV/EBITDA with its 5-year range

EV/EBITDA each weekMiddle half of the last 5 years5-year median 16.6×

5-year median: 16.6×
10-year median: 15.1×
5-year low to high: 7.5×–78.0×
Versus 5-year median: -34%

EV/EBITDA

29thpercentile

of its weekly readings over the last five years

Below its usual range

Growth, last 12 months vs the year before

Revenue: +13%accelerating
EPS: n/a

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading

EV/EBITDA at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

JAZZ EV/EBITDA at each year-end
Year-end	EV/EBITDA	5-year percentile
Dec 29, 2025	76.8×	99
Dec 30, 2024	8.9×	4
Dec 25, 2023	16.1×	57
Dec 26, 2022	16.6×	72
Dec 27, 2021	17.8×	97
Dec 28, 2020	16.3×	91
Dec 30, 2019	10.2×	9
Dec 31, 2018	11.4×	1
Dec 25, 2017	13.9×	22
Dec 26, 2016	13.3×	14

Health Care peers on EV/EBITDA

Each percentile compares a stock with its own last five years.

Compare JAZZ with peers

Health Care peers of JAZZ on EV/EBITDA
Stock	EV/EBITDA	Versus its own history	5-year percentile
AXSMAxsome Therapeutics Inc	n/a	Not ranked	n/a, not ranked
BMYBristol Myers Squibb	9.6×	Within its usual range	45
CORTCorcept Therapeutics Inc	n/a	Not ranked	n/a, not ranked
ELANElanco Animal Health Inc	n/a	Not ranked	n/a, not ranked
JNJJohnson & Johnson	25.5×	Historically high	100

Appears in

Sector: Health Care
Screens: Stocks with Low P/E Ratios and Steady Revenue Growth
Stocks Below Their 5-Year Median P/E
Stocks Near Their Lowest P/E Ratios in 5 Years

Screen Health Care stocks the same way

Research on JAZZ

No articles about JAZZ yet. How valuation percentiles work

Loading peers and related research…

About this history

What is JAZZ's current EV/EBITDA?: JAZZ's EV/EBITDA of 10.9x is lower than 71% of its weekly readings over the last five years.
What is JAZZ's five-year median EV/EBITDA?: 16.6x. Half of JAZZ's weekly readings over the last five years were higher and half were lower. This page has 765 weekly readings, from Feb 27, 2012 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares JAZZ only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.